Open AccessHuman Pharmacokinetics and Adverse Effects of Pulmonary and Intravenous THC-CBD Formulations
Author(s) -
Pascale Meyer,
Manuela Langos,
Rudolf Brenneisen
Publication year - 2018
Publication title -
medical cannabis and cannabinoids
Language(s) - English
Resource type - Journals
ISSN - 2504-3889
DOI - 10.1159/000489034
Subject(s) - pharmacokinetics , cannabidiol , bioavailability , pharmacology , adverse effect , medicine , absorption (acoustics) , chemistry , cannabinoid , anesthesia , cannabis , psychiatry , physics , receptor , acoustics
Due to variable absorption and extensive first-pass metabolism, the bioavailability of oral delta-9-tetra-hydrocannabinol (THC) and cannabidiol (CBD) is low, and, therefore, alternative application forms are necessary.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom